Better response to Tanreqing injection in frequent acute exacerbation of chronic obstructive pulmonary disease (AECOPD) patients-Real-world evidence from a nationwide registry (ACURE) study
- PMID: 37056988
- PMCID: PMC10086601
- DOI: 10.3389/fphar.2023.1118143
Better response to Tanreqing injection in frequent acute exacerbation of chronic obstructive pulmonary disease (AECOPD) patients-Real-world evidence from a nationwide registry (ACURE) study
Abstract
Objective: Our aim was to systematically investigate the efficacy of Tanreqing (TRQ) injection on in-hospital outcomes among inpatients with frequent or infrequent AECOPD. Methods: In this ongoing, nationwide multicenter registry designed to investigate clinical characteristics, management, and prognoses of Chinese patients admitted for AECOPD in real-world settings, we collected characteristics, comorbidities, in-hospital prognoses, and information on the COPD assessment test (CAT) questionnaire, PEACE questionnaire, and modified British Medical Research Council (mMRC) questionnaire from each enrolled patient. Frequent AECOPD was determined as being admitted to the hospital ≥1 time or visiting the emergency room (ER) ≥ 2 times due to AECOPD within a year. A propensity match method and univariable and multivariable regression models were performed to analyze the efficacy of TRQ on clinical outcomes for inpatients with frequent AECOPD. Results: A total of 4135 inpatients were involved in the analysis, including 868 administered with TRQ and 3267 not administered with TRQ. After propensity score match, among those administered with TRQ, 493 had frequent AECOPD and 358 had infrequent AECOPD. A significant reduction of CAT score at discharge (TRQ median 12, IQR 8.0-16.0; non-TRQ median 13, IQR 9.0-18.0, p = 0.0297), a lower rate of ICU admission (TRQ 0.8% vs. non-TRQ 2.6%, p = 0.0191), and a shorter length of stay (LOS) (TRQ median 11, IQR 9.0-14.0; non-TRQ median 11, IQR 8.0-14.0, p = 0.004) were observed in the TRQ group, compared with the non-TRQ group among frequent AECOPD patients. In the subgroup analysis, for those with a PEACE score >7 on admission, TRQ contributed to a significantly lower CAT score at discharge (p = 0.0084) and a numerically lower ICU admission rate with a marginal statistical significance. Among those with phlegm-heat symptom complex on admission ≥2, a lower CAT score at discharge and a lower ICU admission were also observed in the TRQ group. Conclusion: TRQ injection had better efficacy in patients with frequent AECOPD in reducing ICU admission and alleviating respiratory symptoms, especially for those with higher severity on admission or more phlegm-heat symptoms.
Keywords: Tanreqing injection; comparative study; efficacy; frequent AECOPD; real-world.
Copyright © 2023 Fan, Wang, Wu, Li, Ren, Dong, Huang, Chen, Zhang, Wang and Yang.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Similar articles
-
Network pharmacology combined with pharmacodynamics revealed the anti-inflammatory mechanism of Tanreqing capsule against acute-exacerbation chronic obstructive pulmonary disease.Sci Rep. 2022 Aug 17;12(1):13967. doi: 10.1038/s41598-022-18326-1. Sci Rep. 2022. PMID: 35978041 Free PMC article.
-
Characteristics, Management and In-Hospital Clinical Outcomes Among Inpatients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease in China: Results from the Phase I Data of ACURE Study.Int J Chron Obstruct Pulmon Dis. 2021 Feb 25;16:451-465. doi: 10.2147/COPD.S281957. eCollection 2021. Int J Chron Obstruct Pulmon Dis. 2021. PMID: 33658775 Free PMC article. Review.
-
Clinical and economic burden of comorbid coronary artery disease in patients with acute exacerbation of chronic obstructive pulmonary disease: sex differences in a nationwide cohort study.Respir Res. 2022 Feb 12;23(1):28. doi: 10.1186/s12931-022-01945-7. Respir Res. 2022. PMID: 35151338 Free PMC article.
-
Methylxanthine Treatment in Patients Hospitalized for Acute Exacerbation of Chronic Obstructive Pulmonary Disease in China: A Real-World Study Using Propensity Score Matching Analysis.Front Pharmacol. 2022 Jan 25;13:802123. doi: 10.3389/fphar.2022.802123. eCollection 2022. Front Pharmacol. 2022. PMID: 35145412 Free PMC article.
-
Clinical Efficacy and Safety of Tanreqing Injection for Pulmonary Infection in Patients with Tuberculosis: A Meta-Analysis.J Altern Complement Med. 2018 Nov;24(11):1051-1062. doi: 10.1089/acm.2018.0020. Epub 2018 Aug 20. J Altern Complement Med. 2018. PMID: 30124323
Cited by
-
Effects of Tanreqing injection on the gut microbiota in healthy volunteers.Front Cell Infect Microbiol. 2024 Oct 4;14:1428476. doi: 10.3389/fcimb.2024.1428476. eCollection 2024. Front Cell Infect Microbiol. 2024. PMID: 39431053 Free PMC article.
References
-
- Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (2017). Global initiative for chronic obstructive lung disease (GOLD) committees. Available at: https://goldcopd.org/wp-content/uploads/2017/02/wms-GOLD-2017-FINAL.pdf (Accessed December 1, 2018). - PubMed
-
- Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (2022). Global initiative for chronic obstructive lung disease (GOLD) committees. Available at: https://goldcopd.org/wp-content/uploads/2021/12/GOLD-REPORT-2022-v1.1-22... (Accessed November 3, 2022). - PubMed
-
- Han X. X., Tian Y. G., Liu X. F., Zhao D., Du X. H., Dong H. R., et al. (2022). Network pharmacology combined with pharmacodynamics revealed the anti-inflammatory mechanism of Tanreqing capsule against acute-exacerbation chronic obstructive pulmonary disease. Sci. Rep. 12 (1), 13967. 10.1038/s41598-022-18326-1 - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous